Sermorelin & GHRP-2 & GHRP-6 vs BNP (B-type Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin & GHRP-2 & GHRP-6
A powerful tri-blend combining Sermorelin (a GHRH analog) with two growth hormone releasing peptides. This combination produces significantly greater GH release than any single peptide, with studies showing up to 54-fold increases in pulsatile GH secretion.
Full details →BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin & GHRP-2 & GHRP-6 | BNP (B-type Natriuretic Peptide) |
|---|---|---|
| Mechanism | Sermorelin stimulates the pituitary via GHRH receptors, while GHRP-2 and GHRP-6 act as ghrelin mimetics on different receptor subtypes. The combination creates synergistic GH release through multiple complementary pathways. GHRP-6 also strongly stimulates appetite. | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. |
| Typical Dosage | Typical protocols: Sermorelin 100-300mcg, GHRP-2 100-300mcg, GHRP-6 100-300mcg. Often administered 2-3 times daily, 30 minutes before meals or at bedtime. | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. |
| Administration | Subcutaneous injection. Best administered fasted or before sleep to maximize natural GH cycle. The three peptides can be mixed together or administered separately. | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. |
| Side Effects | Increased hunger (especially from GHRP-6), water retention, facial flushing, nausea, tingling, potential increases in cortisol and prolactin levels. | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. |
| Best For |